March 2026 Peptide Research Updates
New peptides added, latest clinical trial results, FDA/EMA news for March 2026.
New Peptide Profiles Added
The following peptide profiles were added or significantly expanded this month:
| Peptide | Category | Highlights |
|---|---|---|
| Pinealon | Bioregulator / Neuro | Khavinson pineal gland peptide; neuroprotective and circadian rhythm research |
| Prostamax | Bioregulator | Prostate-targeting bioregulator from the Khavinson family |
| Testagen | Bioregulator | Testicular bioregulator for hormonal support research |
| Thymosin Beta-10 | Immune / Cancer | Actin-sequestering peptide with roles in immune cell migration and cancer biology |
| Thymosin Beta-4 Sulfoxide | Immune / Anti-inflammatory | Oxidized TB-4 form with distinct glucocorticoid-like anti-inflammatory profile |
| Maritide | Metabolic | Next-generation metabolic peptide in clinical development |
| Pemvidutide | Metabolic | Dual GLP-1/glucagon receptor agonist for NASH and obesity |
New Research Articles
- GLP-1 Agonist Comparison — Head-to-head data table: semaglutide vs tirzepatide vs retatrutide vs cagrilintide vs orforglipron
- BPC-157 Complete Guide — Definitive reference: all forms, routes, doses, and research
- TB-500 Complete Guide — Comprehensive thymosin beta-4 research reference
- GHK-Cu Complete Guide — All GHK-Cu research consolidated
- Epithalon Complete Guide — Khavinson telomere research and protocols
- Peptide Stacking Guide — Research-based combinations: healing, GH, nootropic, longevity, metabolic, cosmetic stacks
- Peptide Storage & Reconstitution — Complete storage, BAC water, freeze-thaw, and stability reference
- Peptide Administration Guide — SC, IM, intranasal, sublingual, oral technique guide
New Categories
The wiki has expanded from 7 to 16 categories for more precise classification:
- Thymic & Immune Peptides — Thymus-derived and thymic peptides
- Antimicrobial Peptides — Host defense and antimicrobial peptides
- Pain & Nociception — Pain signaling and analgesic peptides
- Cardiovascular Peptides — Heart, vascular, and circulatory peptides
- Sexual & Reproductive Health — PT-141, kisspeptin, GnRH analogs
- Russian Bioregulators — Complete Khavinson peptide family
- Cosmetic & Topical — Complete Guide — Expanded cosmetic peptide reference
- Fragments & Analogs — Peptide fragments, modifications, and blends
- Oral Peptides — Peptides with oral bioavailability
Regulatory & Industry News
FDA/EMA Updates (March 2026)
- Retatrutide (Eli Lilly): Phase 3 TRIUMPH program continues enrollment for triple-agonist GIP/GLP-1/glucagon receptor agonist
- Orforglipron (Eli Lilly): Phase 3 ACHIEVE program for oral non-peptide GLP-1R agonist advancing
- CagriSema (Novo Nordisk): Phase 3 REDEFINE program for cagrilintide + semaglutide combination ongoing
- Pemvidutide (Altimmune): Phase 2b results for NASH and obesity continue to show promise
Research Highlights
- Continued expansion of GLP-1 agonist cardiovascular outcomes data, with SELECT trial long-term follow-up supporting sustained MACE reduction
- Growing interest in bioregulator peptides outside Russia, with Western labs beginning to replicate Khavinson's gene expression findings
- Antimicrobial peptide research intensifying amid global antibiotic resistance concerns